CIK 0001658551
- Non-accelerated filer
- Smaller reporting company
Amylyx Pharmaceuticals, Inc.
Sign in to watch- Ticker
- AMLX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 464600503
- Phone
- +1 617-682-0917
- Business address
- 55 CAMBRIDGE PARKWAY, SUITE 6W, CAMBRIDGE, MA, 02142
- 4 Option exercise Chief Commercial Officer acquired 25,000 shares (option exercise)
- 4 Open-market buy Director bought 4,000 shares at $14.97 ($59,880)
- 4 Grant or award Chief Medical Officer acquired 58,333 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 4 Option exercise Co-Chief Executive Officer acquired 63,694 shares (option exercise)
- 4 Gift Chief Financial Officer gave 11,072 shares (gift)
- 4 Option exercise Chief Financial Officer acquired 18,165 shares (option exercise)
- 4 Gift 10% owner gave 2,000,000 shares (gift)
- 4 Planned sale Chief Legal Officer sold 6,164 shares at $20.88 ($128,686)
- 4 Option exercise Chief Commercial Officer acquired 20,000 shares (option exercise)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Gift Chief Commercial Officer gave 1,580 shares (gift)
- 4 Gift Chief Legal Officer gave 500 shares (gift)
- 4 Planned sale Chief Financial Officer sold 32,500 shares at an average $26.94 ($875,451)
- 4 Planned sale Chief Medical Officer sold 11,965 shares at $29.03 ($347,358)
- 4/A Conversion Chief Financial Officer acquired 19,482 shares (conversion)
- 3/A Insider 3/A
Page 7 of 11 · 207 filings